Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure

F1000Research

Volumn 6, Issue , 2017, Pages

  Hoeng, Julia ^a   Boué, Stéphanie ^a   Exner, Thomas ^b   Ghosh, Samik ^c   Belcastro, Vincenzo ^a   Dokler, Joh ^b   Page, David ^a   Boda, Akash ^a   Bonjour, Filipe ^a   Hardy, Barry ^b   Vanscheeuwijck, Patrick ^a   Peitsch, Manuel ^a  

^a Philip Morris Products SA   (Switzerland)

^b Douglas Connect GmbH   (Switzerland)

^c SBX Corporation   (Japan)

Author keywords

Data sharing; Database; Harm reduction; Open data; Systems toxicology; Website

Indexed keywords

ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; GENE EXPRESSION; HISTOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPIDOMICS; MORPHOMETRY; OXIDATIVE STRESS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY; RISK FACTOR; SMOKING; TRANSCRIPTOMICS;

EID: 85028674134     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10493.2     Document Type: Article

References (56)

1. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health: The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Reports of the Surgeon General.2014. 24455788
2. Family Smoking Prevention and Tobacco Control Act.Public Law No. 111-131;2009. Reference Source
3. Smith MR Clark B Lüdicke F: Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regul Toxicol Pharmacol. 2016;81(Suppl 2):S17-S26. 27450400 10.1016/j.yrtph.2016.07.006
4. Foods and Drugs Administration: 81 FR 58341 - Good laboratory Practice for Nonclinical Laboratory Studies.2016. Reference Source
5. Rabesandratana T: REGULATORY SCIENCE. Europe's food watchdog embraces transparency. Science. 2015;350(6259):368. 26494739 10.1126/science.350.6259.368
6. Begley CG Ioannidis JP: Reproducibility in science: improving the standard for basic and preclinical research. Circ Res. 2015;116(1):116-126. 25552691 10.1161/CIRCRESAHA.114.303819
7. Couchman JR: Peer review and reproducibility. Crisis or time for course correction? J Histochem Cytochem. 2014;62(1):9-10. 24217925 10.1369/0022155413513462 3873808
8. Drubin DG: Great science inspires us to tackle the issue of data reproducibility. Mol Biol Cell. 2015;26(21):3679-3680. 26515968 10.1091/mbc.E15-09-0643 4626049
9. Frye SV Arkin MR Arrowsmith CH: Tackling reproducibility in academic preclinical drug discovery. Nat Rev Drug Discov. 2015;14(11):733-734. 26388229 10.1038/nrd4737
10. Gaudart J Huiart L Milligan PJ: Reproducibility issues in science, is P value really the only answer? Proc Natl Acad Sci U S A. 2014;111(19):E1934. 24760820 10.1073/pnas.1323051111 4024892
11. Iorns E Chong C: New forms of checks and balances are needed to improve research integrity. F1000Res. 2014;3:119. 25324963 10.12688/f1000research.3714.1 4197740
12. Nature Editorial: Announcement: Reducing our irreproducibility. Nature. 2013;496:398. 10.1038/496398a
13. McNutt M: Journals unite for reproducibility. Science. 2014;346(6210):679. 25383411 10.1126/science.aaa1724
14. Morven Dialogues: Core Principles Concerning the Implementation of Effective and Workable Tobacco, Nicotine, and Alternative Products Policies for Reducing Disease and Death from Tobacco Use.2015. Reference Source
15. Kryshtafovych A Moult J Bales P: Challenging the state of the art in protein structure prediction: Highlights of experimental target structures for the 10th Critical Assessment of Techniques for Protein Structure Prediction Experiment CASP10. Proteins. 2014;82(Suppl 2):26-42. 24318984 10.1002/prot.24489 4072496
16. Hirschman L Yeh A Blaschke C: Overview of BioCreAtIvE: critical assessment of information extraction for biology. BMC Bioinformatics. 2005;6(Suppl 1):S1. 15960821 10.1186/1471-2105-6-S1-S1 1869002
17. Stolovitzky G Monroe D Califano A: Dialogue on reverse-engineering assessment and methods: the DREAM of high-throughput pathway inference. Ann N Y Acad Sci. 2007;1115:1-22. 17925349 10.1196/annals.1407.021
18. Meyer P Alexopoulos LG Bonk T: Verification of systems biology research in the age of collaborative competition. Nat Biotechnol. 2011;29(9):811-5. 21904331 10.1038/nbt.1968
19. Saez-Rodriguez J Costello JC Friend SH: Crowdsourcing biomedical research: leveraging communities as innovation engines. Nat Rev Genet. 2016;17(8):470-486. 27418159 10.1038/nrg.2016.69
20. Majeed S Frentzel S Wagner S: Characterization of the Vitrocell® 24/48 in vitro aerosol exposure system using mainstream cigarette smoke. Chem Cent J. 2014;8(1):62. 25411580 10.1186/s13065-014-0062-3 4236458
21. Sturla SJ Boobis AR FitzGerald RE: Systems toxicology: from basic research to risk assessment. Chem Res Toxicol. 2014;27(3):314-329. 24446777 10.1021/tx400410s 3964730
22. Hoeng J Deehan R Pratt D: A network-based approach to quantifying the impact of biologically active substances. Drug Discov Today. 2012;17(9-10):413-418. 22155224 10.1016/j.drudis.2011.11.008
23. National Research Council: Toxicity Testing in the 21st Century: A Vision and a Strategy.2007. Reference Source
24. Hartung T: Lessons learned from alternative methods and their validation for a new toxicology in the 21st century. J Toxicol Environ Health B Crit Rev. 2010;13(2-4):277-290. 20574902 10.1080/10937404.2010.483945
25. Krewski D Acosta D Jr Andersen M: Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev. 2010;13(2-4):51-138. 20574894 10.1080/10937404.2010.483176 4410863
26. Organisation for Economic Co-operation and Development: Guidance document on developing and assessing adverse outcome pathways. Series on Testing and Assessment. 2013;184. Reference Source
27. Horvat T Landesmann B Lostia A: Adverse outcome pathway development from protein alkylation to liver fibrosis. Arch Toxicol. 2016;1-21. 27542122 10.1007/s00204-016-1814-8 5364266
28. Ansari S Baumer K Boué S: Comprehensive systems biology analysis of a 7-month cigarette smoke inhalation study in C57BL/6 mice. Sci Data. 2016;3: 150077. 26731301 10.1038/sdata.2015.77 4700839
29. Kogel U Schlage WK Martin F: A 28-day rat inhalation study with an integrated molecular toxicology endpoint demonstrates reduced exposure effects for a prototypic modified risk tobacco product compared with conventional cigarettes. Food Chem Toxicol. 2014;68:204-217. 24632068 10.1016/j.fct.2014.02.034
30. Kogel U Gonzalez Suarez I Xiang Y: Biological impact of cigarette smoke compared to an aerosol produced from a prototypic modified risk tobacco product on normal human bronchial epithelial cells. Toxicol In Vitro. 2015;29(8):2102-2115. 26277032 10.1016/j.tiv.2015.08.004
31. Phillips B Veljkovic E Peck MJ: A 7-month cigarette smoke inhalation study in C57BL/6 mice demonstrates reduced lung inflammation and emphysema following smoking cessation or aerosol exposure from a prototypic modified risk tobacco product. Food Chem Toxicol. 2015;80:328-345. 25843363 10.1016/j.fct.2015.03.009
32. Hoeng J Talikka M Martin F: Case study: the role of mechanistic network models in systems toxicology. Drug Discov Today. 2014;19(2):183-192. 23933191 10.1016/j.drudis.2013.07.023
33. Hardy B Douglas N Helma C: Collaborative development of predictive toxicology applications. J Cheminform. 2010;2(1):7. 20807436 10.1186/1758-2946-2-7 2941473
34. Hardy B Apic G Carthew P: Toxicology ontology perspectives. ALTEX. 2012;29(2):139-156. 22562487 10.14573/altex.2012.2.139
35. Miller GW: Data sharing in toxicology: beyond show and tell. Toxicol Sci. 2015;143(1):3-5. 25538267 10.1093/toxsci/kfu237
36. Judson R Richard A Dix DJ: The toxicity data landscape for environmental chemicals. Environ Health Perspect. 2009;117(5):685-95. 19479008 10.1289/ehp.0800168 2685828
37. Davis AP Murphy CG Saraceni-Richards CA: Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res. 2009;37(Database issue):D786-792. 18782832 10.1093/nar/gkn580 2686584
38. Lea IA Gong H Paleja A: CEBS: a comprehensive annotated database of toxicological data. Nucleic Acids Res. 2016; pii: gkw1077. 27899660 10.1093/nar/gkw1077 5210559
39. Iskandar AR Mathis C Martin F: 3-D nasal cultures: Systems toxicological assessment of a candidate modified-risk tobacco product. ALTEX. 2016, In press. 27388676 10.14573/altex.1605041
40. Zanetti F Sewer A Mathis C: Systems Toxicology Assessment of the Biological Impact of a Candidate Modified Risk Tobacco Product on Human Organotypic Oral Epithelial Cultures. Chem Res Toxicol. 2016;29(8):1252-69, In press. 27404394 10.1021/acs.chemrestox.6b00174
41. Adeleye Y Andersen M Clewell R: Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicology. 2015;332:102-111. 24582757 10.1016/j.tox.2014.02.007
42. Jaworska J Hoffmann S: Integrated Testing Strategy (ITS) - Opportunities to better use existing data and guide future testing in toxicology. ALTEX. 2010;27(4):231-242. 21240466 10.14573/altex.2010.4.231
43. Food and Drug Administration F: Guidance for Industry.2012. Reference Source
44. Wilkinson MD Dumontier M Aalbersberg IJ: The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3:160018. 26978244 10.1038/sdata.2016.18 4792175
45. Kohonen P Benfenati E Bower D: The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing. Mol Inform. 2013;32(1):47-63. 27481023 10.1002/minf.201200114
46. Hendrickx DM Aerts HJ Caiment F: diXa: a data infrastructure for chemical safety assessment. Bioinformatics. 2015;31(9):1505-1507. 25505093 10.1093/bioinformatics/btu827 4410652
47. Jeliazkova N Chomenidis C Doganis P: The eNanoMapper database for nanomaterial safety information. Beilstein J Nanotechnol. 2015;6:1609-1634. 26425413 10.3762/bjnano.6.165 4578352
48. Sansone SA Rocca-Serra P Brandizi M: The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS. 2008;12(2):143-149. 18447634 10.1089/omi.2008.0019
49. Younesi E Ansari S Guendel M: CSEO - the Cigarette Smoke Exposure Ontology. J Biomed Semantics. 2014;5:31. 25093069 10.1186/2041-1480-5-31 4120729
50. Ghosh S Matsuoka Y Asai Y: Software for systems biology: from tools to integrated platforms. Nat Rev Genet. 2011;12(12):821-832. 22048662 10.1038/nrg3096
51. Eddy DM: Evidence-based medicine: a unified approach. Health Aff (Millwood). 2005;24(1):9-17. 15647211 10.1377/hlthaff.24.1.9
52. Stephens ML Andersen M Becker RA: Evidence-based toxicology for the 21st century: opportunities and challenges. ALTEX. 2013;30(1):74-103. 23338808 10.14573/altex.2013.1.074
53. Ghosh S Matsuoka Y Asai Y: Toward an integrated software platform for systems pharmacology. Biopharm Drug Dispos. 2013;34(9):508-526. 24150748 10.1002/bdd.1875 4253131
54. Doe JE Lander DR Doerrer NG: Use of the RISK21 roadmap and matrix: human health risk assessment of the use of a pyrethroid in bed netting. Crit Rev Toxicol. 2016;46(1):54-73. 26517449 10.3109/10408444.2015.1082974 4732465
55. Jaworska JS Natsch A Ryan C: Bayesian integrated testing strategy (ITS) for skin sensitization potency assessment: a decision support system for quantitative weight of evidence and adaptive testing strategy. Arch Toxicol. 2015;89(12):2355-2383. 26612363 10.1007/s00204-015-1634-2
56. Data models to GO-FAIR. Nat Genet. 2017;49(7):971. 28656982 10.1038/ng.3910